Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
COVID-19 – External Monitoring Guidelines
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Although home-based working is utilized as much as possible, activities such as source data verification can only be performed onsite.
RPL is now welcoming CRA visits to recommence by adhering to the following exposure prevention policy that is designed to best mitigate risks posed by COVID-19.
Medicines Marketing UK / EU vs US: Why Your Launch Strategy Needs a Continental Divide - Dr Lisa Campbell, Director of Regulatory Strategy
September 12, 2025
A UK CRO’s perspective on planning clinical trials for global success For pharmaceutical companies preparing for global expansion, launching in both the US and EU / UK markets often seems like the natural next step. Yet success in one region does not guarantee success in the other.
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.